

VICURON PHARMACEUTICALS INC  
Form 8-K  
August 11, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported):**

**August 10, 2004**

---

**Vicuron Pharmaceuticals Inc.**

**(Exact Name of Registrant As Specified in its Charter)**

---

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000-31145**  
**(Commission File Number)**

**04-3278032**  
**(I.R.S. Employer**  
  
**Identification Number)**

Edgar Filing: VICURON PHARMACEUTICALS INC - Form 8-K

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

(610) 205-2300

(Registrant's telephone number, including area code)

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

---

**Item 5. Other Events and Required FD Disclosure.**

On August 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing that it recently completed a Phase II trial of Ramoplanin for the treatment of *Clostridium difficile*-associated diarrhea (CDAD).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.  
(Registrant)

Date: August 11, 2004

By: /s/ George F. Horner III

---

George F. Horner III  
President and Chief Executive Officer